Foundayo is now available for adult patients with obesity and weight-related comorbidities to reduce excess body weight and maintain reduction.

Drug companies AbbVie and Genentech will start selling medications at lower prices through the White House’s "TrumpRx" website.

The recent Food and Drug Administration approvals of oral Wegovy ® (semaglutide) and Foundayo ® (orforglipron) represent a major milestone in obesity treatment, shifting the glucagon-like peptide-1 ...

Low food access (LFA) is associated with increased comorbidities and postoperative complications for women undergoing mastectomy.

On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.

Current BMI classification may overestimate the prevalence of underweight, overweight, and obesity among the general population.

Test your knowledge on the top endocrinology research from March 2026. True or false: According to findings from the ACHIEVE-3 (ClinicalTrials.gov Identifier: NCT06045221) trial, oral orforglipron, ...

Multiple manufacturers receive FDA approval for generic dapagliflozin to treat type 2 diabetes and lower heart failure risks in high-risk T2D patients.

A study of 132,000 children finds that high BMI in mid- to late childhood is the strongest predictor of early pubertal onset.

Researchers identify an optimal visceral adipose tissue range of 46.5-116.6 cm² to minimize the combined risk of diabetes and osteoporosis.

Kinesio taping (KT) for musculoskeletal disorders may reduce pain intensity in the immediate and short term, but the evidence is uncertain.

For adults aged 65 years and older, the risk for incident AD is lower for those who receive a high versus standard dose of IIV.